- Coordinates
 - PDB Format
 - Method
 - ELECTRON MICROSCOPY
 - Oligo State
 - hetero-3-1-1-mer
 - Ligands
 - 28 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
 - 25 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
 NAG.29: 2 residues within 4Å:- Chain A: N.4, N.124
 
Ligand excluded by PLIPNAG.30: 3 residues within 4Å:- Chain A: Y.15, N.17, N.48
 
Ligand excluded by PLIPNAG.31: 3 residues within 4Å:- Chain A: N.112, V.114, V.158
 
Ligand excluded by PLIPNAG.32: 2 residues within 4Å:- Chain A: H.133, N.136
 
Ligand excluded by PLIPNAG.33: 1 residues within 4Å:- Chain A: N.590
 
Ligand excluded by PLIPNAG.34: 2 residues within 4Å:- Chain A: H.642, N.644
 
Ligand excluded by PLIPNAG.35: 4 residues within 4Å:- Chain A: N.696, I.1117, G.1118
 - Chain B: D.783
 
Ligand excluded by PLIPNAG.36: 1 residues within 4Å:- Chain B: N.48
 
Ligand excluded by PLIPNAG.37: 5 residues within 4Å:- Chain B: N.109, T.111, N.112, V.114, E.141
 
Ligand excluded by PLIPNAG.38: 1 residues within 4Å:- Chain B: N.136
 
Ligand excluded by PLIPNAG.39: 4 residues within 4Å:- Chain A: Y.338, I.455
 - Chain B: N.151, N.152
 
Ligand excluded by PLIPNAG.40: 7 residues within 4Å:- Chain A: R.444, N.447, K.449, E.452
 - Chain B: T.95, N.221, T.223
 
Ligand excluded by PLIPNAG.41: 3 residues within 4Å:- Chain A: K.545
 - Chain B: E.268, N.269
 
Ligand excluded by PLIPNAG.42: 1 residues within 4Å:- Chain B: N.590
 
Ligand excluded by PLIPNAG.43: 1 residues within 4Å:- Chain B: N.644
 
Ligand excluded by PLIPNAG.44: 6 residues within 4Å:- Chain B: N.696, I.1117, G.1118
 - Chain C: D.783, G.785, P.886
 
Ligand excluded by PLIPNAG.45: 2 residues within 4Å:- Chain C: Y.15, N.48
 
Ligand excluded by PLIPNAG.46: 4 residues within 4Å:- Chain C: N.109, T.111, N.112, V.114
 
Ligand excluded by PLIPNAG.47: 3 residues within 4Å:- Chain C: N.135, N.136, M.140
 
Ligand excluded by PLIPNAG.48: 4 residues within 4Å:- Chain B: Y.338, I.455
 - Chain C: N.151, N.152
 
Ligand excluded by PLIPNAG.49: 7 residues within 4Å:- Chain B: R.444, N.447, K.449, E.452
 - Chain C: T.95, N.221, T.223
 
Ligand excluded by PLIPNAG.50: 3 residues within 4Å:- Chain C: N.267, N.269, T.273
 
Ligand excluded by PLIPNAG.51: 1 residues within 4Å:- Chain C: N.590
 
Ligand excluded by PLIPNAG.52: 2 residues within 4Å:- Chain C: H.642, N.644
 
Ligand excluded by PLIPNAG.53: 4 residues within 4Å:- Chain A: D.783, P.886
 - Chain C: N.696, I.1117
 
Ligand excluded by PLIP- Links
 - RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
 - Citation
 - Adams, L.J. et al., A broadly reactive antibody targeting the N-terminal domain of SARS-CoV-2 spike confers Fc-mediated protection. Cell Rep Med (2023)
          


 - Release Date
 - 2022-11-23
 - Peptides
 - Spike glycoprotein: ABC
SARS2-57 Fv heavy chain: D
SARS2-57 Fv light chain: E - SMTL:PDB
 - SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
HE
L 
- Coordinates
 - PDB Format
 - Method
 - ELECTRON MICROSCOPY
 - Oligo State
 - hetero-3-1-1-mer
 - Ligands
 - 28 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
 - 25 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
 - Links
 - RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
 - Citation
 - Adams, L.J. et al., A broadly reactive antibody targeting the N-terminal domain of SARS-CoV-2 spike confers Fc-mediated protection. Cell Rep Med (2023)
          


 - Release Date
 - 2022-11-23
 - Peptides
 - Spike glycoprotein: ABC
SARS2-57 Fv heavy chain: D
SARS2-57 Fv light chain: E - SMTL:PDB
 - SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
HE
L